# Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)

> **NCT05270668** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)** · enrollment: 154 (actual)

## Conditions studied

- Diffuse Cutaneous Systemic Sclerosis
- Interstitial Lung Disease

## Interventions

- **DRUG:** Tulisokibart
- **DIAGNOSTIC_TEST:** Companion diagnostic ( CDx)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05270668
- **Lead sponsor:** Prometheus Biosciences, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-03-29
- **Primary completion:** 2026-04-16
- **Final completion:** 2029-07-31
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05270668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05270668, "Phase 2 Safety and Efficacy Study of Tulisokibart (MK-7240/PRA023) in Subjects With Systemic Sclerosis Associated With Interstitial Lung Disease (SSc-ILD) (MK-7240-007)". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT05270668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*